ライフサイエンスコーパス: intravenous drug use

1 She denied any history of recent trauma or intravenous drug use.

2 s POEs) associated with health care and with intravenous drug use.

3 cases occur in individuals with a history of intravenous drug use.

4 rican race, and have a history of alcohol or intravenous drug use.

5 type of operation, age, sex, and history of intravenous drug use.

6 hetic hip joints but not in association with intravenous drug use.

7 or identified for HCV NAT-reactive donors is intravenous drug use.

8 American participants more commonly reported intravenous drug use.

9 es (n = 32), the disease was associated with intravenous drug use.

10 ding trauma, systemic illness, or history of intravenous drug use.

11 Intravenous drug use.

12 with occasional partners (2.01; 1.36-2.98), intravenous drug use (7.13; 4.36-11.64), noninjectable d

13 l exposures accounted for 17 infections, and intravenous drug use accounted for 6.

14 re to infection, bleeding, immunodeficiency, intravenous drug use, alcohol or tobacco abuse, history

15 ry of infection, bleeding, immunodeficiency, intravenous drug use, alcohol or tobacco abuse, malignan

16 o all others (P = .035), after adjusting for intravenous drug use and ART.

17 frequently associated with remote or current intravenous drug use and blood transfusion before 1992,

18 We show that homelessness, intravenous drug use, and alcohol abuse predisposed pati

19 epatitis B surface antigen (HBsAg) carriers, intravenous drug use, and homosexual/bisexual practices.

20 cts of homelessness, jail stay, promiscuity, intravenous drug use, and other drug use.

21 hree were men, 35% were nonwhite, and 6% had intravenous drug use as a risk factor.

22 urrent event model controlling for age, sex, intravenous drug use, cART start year, cART type, assay

23 by previous SARS-CoV-2 exposure, ethnicity, intravenous drug use, CD4 counts and HIV viremia as inde

24 icantly increased, whereas the prevalence of intravenous drug use decreased.

25 rise among young adults owing to the ongoing intravenous drug use epidemic.

26 Intravenous drug use filter settings changed most, from

27 ; P < .01) when accounting for maternal age, intravenous drug use, geographic origin, and CD4 cell co

28 of transmission from vertical infection and intravenous drug use has decreased.

29 whose presumed mode of transmission was via intravenous drug use (hazard ratio 0.27, 0.12-0.61) than

30 edure, reoperations, infective endocarditis, intravenous drug use, hemodialysis, and out-of-state res

31 Older age, intravenous drug use, hepatitis C coinfection, lower bas

32 The patient had no history of rash, intravenous drug use, immunosuppressive medication use,

33 cocaine use in 169 (68 percent, P < 0.001), intravenous drug use in 103 (42 percent, P = 0.001), sex

34 Intravenous drug use is associated with increased risk o

35 dex (BMI) >= 25 kg/m2 (P = .055), history of intravenous drug use (IVDU) (P = .033), and nadir CD4 co

36 y of increased risk behavior (IRB) including intravenous drug use (IVDU), imprisonment and increased

37 ng 192 patients who received treatment: age; intravenous drug use (IVDU); specific type of sexual con

38 past year, immunocompromised health status, intravenous drug use, long-term hemodialysis, and known

39 is increasing, driven in part by the rise in intravenous drug use, mostly opioids and stimulant drugs

40 use (n=79), oral narcotic abuse (n=20), and intravenous drug use (n=21).

41 nfidence interval: 1.72, 10.40; p=0.002) and intravenous drug use (odds ratio=6.06, 95% confidence in

42 us bacteremia on native heart valves without intravenous drug use or clinically apparent metastatic i

43 lly observed with acute HCV acquisition from intravenous drug use or sexual activity.

44 betes with chronic complications (OR, 1.96), intravenous drug use (OR, 3.12), radiation therapy (OR,

45 e (P < 0.01), and patients with a history of intravenous drug use (P < 0.01).

46 rhosis, diabetes with chronic complications, intravenous drug use, radiation therapy, and solid organ

47 r blood transfusion, intranasal cocaine use, intravenous drug use, sexual promiscuity, and ear pierci

48 Older age, lower education level, intravenous drug use, smoking, lower CD4-cell count, hig

49 of endocarditis is changing with the rise of intravenous drug use; staphylococci are an increasingly

50 easures--self-reported cocaine, alcohol, and intravenous drug use, unsafe sex, and reincarceration--w

51 The high frequency of intravenous drug use was unexpected, because these donor

52 one traditional risk factor (transfusion or intravenous drug use) was reported by 30.2% of all subje

53 d infective endocarditis not associated with intravenous drug use were compared with community reside

54 ommunity-acquired IE cases unassociated with intravenous drug use were compared with matched communit